Elanco Animal Health (ELAN) Other Non-Current Assets (2017 - 2026)
Elanco Animal Health (ELAN) reported Other Non-Current Assets of $295.0 million for Q1 2026, down 5.45% on a YoY basis from $312.0 million in Q1 2025, and down 2.96% sequentially from $304.0 million in Q4 2025.
Elanco Animal Health (ELAN) Other Non-Current Assets (2017 - 2026) Analysis & Trends
Elanco Animal Health (ELAN) has 10 years of Other Non-Current Assets data on file, last reported at $295.0 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets fell 5.45% year-over-year to $295.0 million; the trailing twelve-month figure through Mar 2026 stood at $295.0 million (down 5.45% YoY), and the FY2025 full-year result was $304.0 million, down 2.25% from the prior year.
- Other Non-Current Assets fell to $295.0 million in Q1 2026, from $304.0 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $559.0 million in Q1 2022 to a low of $295.0 million in Q1 2026.
- A 5-year average of $355.1 million and a median of $341.0 million in 2023 frame the typical range for Other Non-Current Assets.
- Across the five-year window, Other Non-Current Assets jumped 72.0% in 2022 and slumped 33.99% in 2023, its largest moves.
- Tracing ELAN's Other Non-Current Assets over 5 years: stood at $378.0 million in 2022, then retreated by 9.79% to $341.0 million in 2023, then decreased by 8.8% to $311.0 million in 2024, then dropped by 2.25% to $304.0 million in 2025, then decreased by 2.96% to $295.0 million in 2026.
- Business Quant data shows ELAN's Other Non-Current Assets at $295.0 million in Q1 2026, $304.0 million in Q4 2025, and $306.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | 49.22 Mn |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 377.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 351.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 491.06 Mn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 233.20 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | 169,000.00 |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 1.11 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 73.60 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 295.00 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 4.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 295.00 Mn |
| Dec 31, 2025 | 304.00 Mn |
| Sep 30, 2025 | 306.00 Mn |
| Jun 30, 2025 | 308.00 Mn |
| Mar 31, 2025 | 312.00 Mn |
| Dec 31, 2024 | 311.00 Mn |
| Sep 30, 2024 | 302.00 Mn |
| Jun 30, 2024 | 324.00 Mn |
| Mar 31, 2024 | 346.00 Mn |
| Dec 31, 2023 | 341.00 Mn |
| Sep 30, 2023 | 410.00 Mn |
| Jun 30, 2023 | 419.00 Mn |
| Mar 31, 2023 | 369.00 Mn |
| Dec 31, 2022 | 378.00 Mn |
| Sep 30, 2022 | 376.00 Mn |
| Jun 30, 2022 | 376.00 Mn |
| Mar 31, 2022 | 559.00 Mn |
| Dec 31, 2021 | 390.00 Mn |
| Sep 30, 2021 | 357.00 Mn |
| Jun 30, 2021 | 375.00 Mn |